We study the immune mechanisms of action of vaccines and vaccine adjuvants, using murine models and ex vivo human secondary lymphoid tissue. An additional line of research are single-dose vaccine formulations. Here the aim is to deliver prime-bost vaccination with a single administration, where the booster vaccine is encapsulated into delayed burst-release polymer particles.


The focus of our group are studies of immune mechanisms underlying vaccine immunogenicity and efficacy, with a specific emphasis on vaccine adjuvants. Adjuvants include a diverse range of compounds that have the ability to potentiate vaccine efficacy.

Our current research includes exploring the mechanism of action of adjuvanted vaccines using different vaccine platforms and clinically-compatible adjuvants developed by the Vaccine Formulation Institute (VFI) in Geneva. In late 2019 we initiated the VFI-Oxford Adjuvant Programme of research with three primary goals: a) understand the types of responses induced by different clinically-compatible adjuvants, b) characterise the adjuvant immunogenicity profiles using clinically relevant antigens and c) assess vaccine efficacy through challenge studies in pre-clinical models of disease. These questions are being addressed through spatio-temporal studies of the innate and adaptive immune responses to adjuvanted vaccines, using an established mouse model of malaria.

Together with Prof. Mark Coles and Dr Calliope Dendrou, and with the support from the Chan Zuckerberg Initiative, we are studying the initial events in adjuvant-induced inflammation ex vivo. Using adjuvant-stimulated human secondary lymphatic tissue, in combination with single cell transcriptomics and hyperplexed imaging, we aim to create a high-resolution map of the early innate immune responses to clinically relevant vaccine adjuvants.

Additionally, in collaboration with the Institute for Biomedical Engineering (IBME), we are developing new microfluidics-based vaccine encapsulation technologies for controlled vaccine release. The aim is to achieve single-dose immunisation that could replace the standard prime-boost approach: the booster vaccine is encapsulated into microcapsules and delivered together with the prime, for delayed burst release within the body.

Our team

Selected publications